Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-25
2005-01-25
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S237000
Reexamination Certificate
active
06846821
ABSTRACT:
The compounds of formula (I) in which R1, R2, A and Ar have the meanings as given in the description are novel effective PDE4 inhibitors.
REFERENCES:
patent: 6103718 (2000-08-01), Sterk
patent: 6255303 (2001-07-01), Sterk et al.
patent: 6380196 (2002-04-01), Ulrich et al.
patent: 6544993 (2003-04-01), Sterk
patent: 0 763 534 (1997-03-01), None
patent: WO 9412461 (1994-06-01), None
patent: WO 9931071 (1999-06-01), None
Doherty, PubMed Abstract (Current Opin Chem Biol. 3(4):466-73), Aug. 1999.*
Schudt, Christian, et al., “Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai”,Naunyn-Schmiedeberg's Arch Pharmacol, 344, pp 682-690, (1991).
Hatzelmann, Armin, et al., “Enzymatic and Functional Aspects of Dual-selective PDE3/4 Inhibitors”,The Handbook of Immunopharmacology, Phosphodiesterase Inhibitors, Academic Press, pp. 147-160, (1996).
Bauer, Anna C., et al., “An Improved Assay of Cyclic 3′, 5′-Nucleotide Phosphodiesterases with QAE-Sephadex Columns”Naunyn-Schmiedeberg's Arch Pharmacol, vol. 311, pp 193-198, (1980).
Giembycz, Mark A., “Could Isoenzyme-Selective Phosphoieterase Inhibitors Render Bronchodilator Therapy Redundant in the Treatment of Bronchial Asthma?” Biochemical Pharmacology, vol. 43, No. 10, pp. 2041-2051, (1992).
McPhail, Linda C., et al., “The Neutrophil Respiratory Burst Mechanism”,Immunology Series, ed. Coffey RG, vol. 57, pp. 47-76, (1992).
Torphy, Theodore J., et al., “Phosphodiesterase inhibitors: new opportunities for the treatment of asthma”,Thorax, vol. 46, pp. 512-523, (1991).
Tenor, Hermann, et al., “Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods”,The Handbook of Immunopharmacology, Phosphodiesterase Inhibitors, Academic Press, pp. 21-40, (1996).
Schudt, Christian, et al., “Zardaverine: A cyclic AMP Specific PDE III/IV Inhibitor”, New Drugs for Asthma Therapy, pp. 379-402, (1991).
Altana Pharma AG
Juneau Todd L.
McGee Sheldon M.
Nath & Associates PLLC
Rao Deepak
LandOfFree
Tetrahydrothiopy ranphthalazinone derivatives as PDE4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydrothiopy ranphthalazinone derivatives as PDE4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydrothiopy ranphthalazinone derivatives as PDE4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368218